|
 |
|
Actinobac Biomed, Inc., is a new company that focuses its activities on the development of pharmaceutical technologies based on agents that target Leukocyte Function Antigen-1 (LFA-1).
Its lead product, Leukotoxin, is a bacterial toxin that specifically targets white blood cells. In addition to its use as an effective targeted therapy agent for the treatment of hematologic malignancies, abundant evidence in literature suggests that Leukotoxin, or a derived product, can effectively be used to treat infectious diseases such as HIV/AIDS and tuberculosis, as well as many autoimmune diseases including rheumatoid arthritis, multiple sclerosis, Crohn’s disease, type 1 diabetes, Lupus and psoriasis.
Therefore, the company will direct its efforts in three strategic areas. The first, and highest priority, is the development of Leukotoxin as a protein therapeutic for the treatment of hematologic malignancies. The second will focus on the use of Leukotoxin and derived therapeutic peptides or mimetics for the treatment of significant diseases other than hematologic malignancies, including infections and autoimmune diseases. The third area represents an early-stage drug discovery program with Magellan BioScience that will maintain a healthy pipeline of novel therapeutic agents.
For more information, visit www.actinobac.com. |
| |
|
|
| |
|
back to top |
| |
|
|
 |
|
CellXplore is a new, privately held biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.
The company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.
CellXplore’s platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer’s disease, Parkinson’s disease and inflammatory diseases. |
| |
|
|
| |
|
back to top |
| |
|
|
 |
|
Longevica Pharmaceuticals, Inc., is a privately held biotechnology company that is developing novel, proprietary drugs with potential use in the treatment of cancer, degenerative diseases and age-related disorders. The company was formed primarily to commercialize the discoveries demonstrating that inactivation of an alpha kinase, EF2 kinase, protects normal (non-cancer) cells and tissues from the toxic effect of chemotherapy or radiation treatments.
Despite the tremendous progress in drug cancer chemotherapy, most of the drugs used today have a pronounced toxicity effect, killing normal cells along with cancer cells. The work being done by scientists at Longevica may lead to a novel approach in cancer therapy that can significantly improve the efficiency of the current methods of cancer treatment.
The discoveries are also expected to be helpful in treating patients suffering from ischemia, stroke and neurodegenerative disorders such as Alzheimer’s disease by protecting cells and tissues from stress damage. |
| |
|
|
| |
|
back to top |
| |
|
|
 |
|
Snowdon, Inc., is a drug discovery and development company that is focused on three major therapeutic areas with substantial market potential—cancer, acute and chronic pain and infectious diseases. In each of these therapeutic areas, Snowdon has discovered prospective drug candidates that address the urgent need for safe and effective medicine.
Snowdon's proven discovery platform is built for speed, economy and maximum success rate. They employ a battery of proprietary computational tools to rapidly identify high-value molecules from their fast in silico library of vendor-available compounds, which can then be procured for initial biological proof of concept evaluation studies.
Visit Snowdon's web site: www.snowdonpharma.com |
| |
|
|
| |
|
back to top |
| |
|
|
|
